Drugs / Adipose derived allogenic mesenchymal stem cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05521672 | Oct 2022 → Dec 2024 | Crohn disease, intestinal obstruction | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adipose derived allogenic mesenchymal stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05521672 ↗ |
| Known as | adAMSC | “Adipose derived allogenic mesenchymal stem cells (adAMSC)” NCT05521672 ↗ |
| Modality | Cell therapy | “adipose derived allogenic mesenchymals stem cells (adMSC)” NCT05521672 ↗ |
| Route | Other | “administered in the perilesional adipose tissue, through a laparoscopic procedure” NCT05521672 ↗ |